Table 1.
Demographic and biological data of patients per country
| Countries | Senegal | Mali | Guinea-Conakry | Total |
|---|---|---|---|---|
| Sample collection sites | 7 | 6 | 4 | 17 |
| Number of patients enrolled | 119 | 152 | 136 | 407 |
| Female (%) | 94 (79%) | 102 (67%) | 83 (61%) | 279 (69%) |
| Median age (years) | 42 [IQR: 18–65] | 41 [IQR: 18–66] | 38 [IQR: 18–61] | 40 [IQR: 18–66] |
| First-line therapy (2 NRTI+1 NNRTI) | 114 (96%) | 136 (89%) | 129 (95%) | 379 (93%) |
| AZT+3TC+NVP/EFV | 109 | 66 | 80 | 255 |
| D4T+3 TC+NVP/EFV | 1 | 43 | 47 | 91 |
| Other first-line combinations | 4 | 27 | 2 | 33 |
| Second-line therapy (2 NRTI+1 PI) | 5 | 16 | 7 | 28 |
| Median time on ART | 32 [IQR: 6–112] | 39 [IQR: 6–136] | 35 [IQR: 6–108] | 36 [IQR: 6–136] |
| VL>technical cut-off (800 copies/mL) | 31 | 17 | 33 | 81 |
| Median of viral load | 3.63 [IQR: 3–5.48] | 3.94 [IQR: 2.97–6.18] | 3.64 [IQR: 3.07–6.75] | 3.68 [IQR: 2.97–6.75] |
| Virological failure (VL>3log10 copies/mL) | 31 (26%) | 16(11%) | 33 (24%) | 80 (20%) |
| Genotyped | 27 (87%) | 15 (94%) | 28 (85%) | 70 (88%) |
| Any DRM | 19 | 14 | 19 | 52 |
| DRM in patients with virological failure | 70% (n=19/27) | 93% (n=14/15) | 68% (n=19/28) | 74% (n=52/70) |
| Global DRM | 16% (n=19/119) | 9% (n=14/152) | 14% (n=19/136) | 13% (n=52/407) |
AZT: zidovudine; D4T: stavudine; NVP: nevirapine; 3TC: lamivudine; EFV: Efavirenz; ART: antiretroviral therapy; NNRTI: non-nucleoside reverse transcriptase inhibitor; NRTI: nucleoside reverse transcriptase inhibitor; PI: protease inhibitor; VL: viral load; DRM: drug resistance mutation.